Wellington Management Group
KRYS icon

Wellington Management Group’s Krystal Biotech KRYS Stock Holding History

Wellington Management Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Buy
36,936
+26,709
+261% +$7.98M ﹤0.01% 1206
2026
Q1 		$2.64M Sell
10,227
-424
-4% -$113K ﹤0.01% 1503
2025
Q4 		$2.63M Sell
10,651
-230
-2% -$48.4K ﹤0.01% 1532
2025
Q3 		$1.92M Buy
10,881
+728
+7% +$109K ﹤0.01% 1640
2025
Q2 		$1.4M Sell
10,153
-446
-4% -$65.5K ﹤0.01% 1661
2025
Q1 		$1.91M Sell
10,599
-1,105
-9% -$186K ﹤0.01% 1573
2024
Q4 		$1.83M Sell
11,704
-976
-8% -$173K ﹤0.01% 1586
2024
Q3 		$2.31M Buy
12,680
+1,660
+15% +$320K ﹤0.01% 1515
2024
Q2 		$2.02M Buy
11,020
+1,712
+18% +$287K ﹤0.01% 1511
2024
Q1 		$1.66M Buy
+9,308
New +$1.29M ﹤0.01% 1564

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group's KRYS Position: Q2 2026 in Review

Wellington Management Group increased its Krystal Biotech (KRYS) stake by 261% in Q2 2026, buying an estimated $7.98M and bringing the position to 36,936 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1206.

Wellington Management Group first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Wellington Management Group held 36,936 shares of Krystal Biotech worth $13.7M as of Q2 2026.
  • Wellington Management Group bought 26,709 Krystal Biotech shares in Q2 2026, an estimated $7.98M.
  • Krystal Biotech made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1206 holding.
  • Wellington Management Group first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.